Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | LPL | P06858 | 5/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.51 |
| ▸ | CHKA | P35790 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | F11 | P03951 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27092909 | 0.96 | LMNA (0.49) | LMNAMC4RLPLLIPGCHKA | |
| SCHEMBL16121847 | 0.94 | CHKA (0.60) | LMNAMC4RLPLLIPGCHKA | |
| SCHEMBL5254853 | 0.88 | LPL (0.55) | LMNALPLLIPGALDH1A1F11 | |
| SCHEMBL3319981 | 0.88 | LPL (0.54) | LPLLIPGCHKACA2NCF1 | |
| SCHEMBL1354581 | 0.88 | LPL (0.54) | LPLLIPGNCF1ALDH1A1F11 | |
| SCHEMBL18580424 | 0.87 | ALDH1A1 (0.49) | LMNALPLLIPGALDH1A1F11 | |
| SCHEMBL28329043 | 0.87 | LPL (0.58) | LPLLIPGF11ESR2 | |
| SCHEMBL427977 | 0.86 | HRH3 (0.56) | LPLLIPGALDH1A1F11KDM4E | |
| SCHEMBL19211745 | 0.86 | LPL (0.57) | LPLLIPGALDH1A1F11NPC1 | |
| SCHEMBL13974429 | 0.85 | LPL (0.49) | LPLLIPGALDH1A1F11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010936-A | Multi-kinase inhibitor, PROTACs target protein ligand, and synthesis method and application thereof | 杭州医学院 | 2026-05-12 | — | — | CN | disclosed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-4655302-A1 | TYRO3 SELECTIVE INHIBITORS AND USES THEREOF | The University of North Carolina at Chapel Hill (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4548919-A2 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | UCL Business Ltd (GB) | 2025-05-07 | — | — | EP | disclosed |
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| US-20250129065-A1 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | UCL BUSINESS LTD (GB) | 2025-04-24 | — | — | US | disclosed |
| EP-1994016-A2 | 5-PHENYL-3-BENZYL-OXAZOLIDIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007078523-A2 | 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | LMNA 3918/4885MC4R 552/4885LPL 4676/4885 |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | LMNA 4716/4885MC4R 438/4885LPL 4623/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | LMNA 1144/4885MC4R 180/4885LPL 2371/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | LMNA 1698/4885MC4R 3629/4885LPL 263/4885 |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | LMNA 4200/4885MC4R 464/4885LPL 2904/4885 |
| US-20250129065-A1 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | NDC1, DDB1, DDX21 | LMNA 284/4885MC4R 4520/4885LPL 4481/4885 |
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | LMNA 4462/4885MC4R 4175/4885LPL 2558/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | LMNA 3472/4885MC4R 2008/4885LPL 3241/4885 |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | LMNA 2174/4885MC4R 611/4885LPL 2563/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | LMNA 1844/4885MC4R 3540/4885LPL 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.